Roughly one in three of the more than 3 million Americans treated for complicated urinary tract infections each year experiences treatment failure, and until this week the carbapenem antibiotics positioned to address resistant infections could only be delivered through an intravenous line. That constraint ends with the FDA’s June 17 approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic cleared in the United States, developed by Spero Therapeutics in partnership with GSK.
The approval rests on PIVOT-PO, a 1,690-patient global, randomized, double-blind phase III trial that compared oral tebipenem pivoxil (600 mg every six hours) against intravenous imipenem-cilastatin (500 mg every six hours) for seven to ten days. The primary endpoint was composite response at the test-of-cure visit, approximately 17 days after first dose. Tebipenem reached a 58.5% overall success rate versus 60.2% for imipenem-cilastatin, an adjusted treatment difference of negative 1.3 percentage points with a 95% confidence interval of negative 7.5 to 4.8, comfortably within the pre-specified non-inferiority margin of negative 10 percent. That margin matters: the trial was designed to show equivalence against the standard IV treatment in hospitalized patients, not to claim superiority, and the data deliver precisely that.
The trial design itself carries clinical implications worth scrutinizing. PIVOT-PO enrolled hospitalized adults, meaning the non-inferiority claim was established in a population already deemed sick enough for inpatient care. The approved label restricts use to adults with limited or no alternative oral treatment options, so this is not a first-line convenience drug. The safety profile mirrored that of other carbapenems: diarrhea and headache were the most common adverse events, each reported in at least 3% of patients, and all were mild to moderate. That profile is unlikely to create meaningful safety friction with prescribers already familiar with the carbapenem class.
With commercial availability targeted for before year-end 2026, the practical test will be whether payers accept the drug’s position as an IV-to-oral step-down option that reduces hospital resource consumption in a cUTI population driving more than $6 billion annually in US healthcare costs. Watch for the initial formulary tier placements from major pharmacy benefit managers, because those decisions will determine whether the clinical flexibility PIVOT-PO demonstrated translates into actual outpatient utilization.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
